Alicia McLaren
Gerontology · Caro, MINPI 1629602909
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 29.2% of the total.
Across 153 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$860
- Novo Nordisk$307
- Axsome Therapeutics, Inc.$219
- AstraZeneca$146
- Indivior Inc.$142
- Alkermes, Inc.$104
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,92999%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 46 | $860 |
| Novo Nordisk | 16 | $307 |
| Axsome Therapeutics, Inc. | 9 | $219 |
| AstraZeneca | 9 | $146 |
| Indivior Inc. | 7 | $142 |
| Alkermes, Inc. | 6 | $104 |
| Orexo US, Inc. | 6 | $102 |
| Astellas Pharma US Inc | 5 | $101 |
| Pfizer | 4 | $92 |
| Johnson & Johnson(2 entities) | 5 | $88 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Lilly USA, LLC | 4 | $75 |
| Lundbeck LLC | 3 | $68 |
| Exact Sciences | 2 | $46 |
| Merck | 1 | $44 |
| Nestle Healthcare Nutrition Inc. | 2 | $38 |
| Acadia Pharmaceuticals Inc | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 1 | $34 |
| Amgen | 2 | $32 |
| Dexcom, Inc. | 2 | $32 |
| Neurocrine Biosciences, Inc. | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Corium, LLC | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Vertex | 1 | $18 |
| Novartis | 1 | $18 |
| Mylan Specialty L.p. | 1 | $17 |
| Baxter Healthcare | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,944 in reported general payments places this provider in the 85th percentile of 279 gerontology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 59 | $63,606 |
| EliquisApixaban | 58 | $38,398 |
| MounjaroTirzepatide | 38 | $37,218 |
| OzempicSemaglutide | 21 | $20,324 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 104 | $17,867 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $11,794 |
| MyrbetriqMirabegron | 25 | $11,514 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $9,040 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,972 |
| FarxigaDapagliflozin Propanediol | 17 | $8,174 |
| Repatha SyringeEvolocumab | 12 | $6,983 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $5,965 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $2,799 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $2,717 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 162 | $2,586 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $19 | $63,60659 claims |
| PfizerEliquis | $92 | $38,39858 claims |
| Lilly USA, LLCMounjaro | $75 | $37,21838 claims |
| Novo NordiskOzempic | $307 | $20,32421 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $146 | $17,14631 claims |
| MerckJanumet | $44 | $11,79414 claims |
| Astellas Pharma US IncMyrbetriq | $101 | $11,51425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 279 gerontology providers in Michigan.
Other gerontology in Caro
- Steven HolmanCaro$2K
- Gwendolyn WrightGrand Blanc$47K
- Matthew AmanRochester Hills$21K
- Sarah ArnkoffWest Bloomfield$18K
- Deborah GriffinPetoskey$11K
- Angela EmbreeGrand Rapids$10K
- Bethany DalessandroWyandotte$10K
- Gabrielle NadeauJackson$10K
- Cynthera McNeillWest Bloomfield$9K
- Samantha BurgessGrand Rapids$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.